Nanna Therapeutics Ltd.

Astellas Pharma, Inc. has effectively ended its interest in the mitochondrial area after a decision to terminate its only candidate, ASP0367 (bocidelpar/MA-0211) in Phase II/III trials, and remove th

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Visus Licenses Drugs From Cella, Delive

Astellas Pharma, Inc. , the multinational biopharma headquartered in Tokyo with multibillion-dollar operations in the US, was impacted by the same forces that buffeted many in the industry in 2020, in

Astellas Pharma Inc. has paid £12m ($14.9m) upfront to acquire UK bioventure Nanna Therapeutics Ltd. in a move that will give the major Japanese firm new expertise in age-related disorders related